Shalby Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the discussed pages of the transcript. - The company highlights a strong balance sheet with a low gearing ratio (standalone 0.02x, group level 0.11x) and net cash balances, indicating healthy financials without a present need for additional debt. - Focus is on operational and new capex funding internally, with expected operational capex of INR 16-20 crores in FY24, and INR 5-7 crores towards new SOCE units. - No references were made to plans for raising funds through equity or debt in the near future during the Q1 FY24 earnings call segments covered.

- Q1 FY24 operational capex was about INR 4 crores, split evenly between replacement and new capex. - Expected operational capex for FY24 is between INR 16-20 crores. - New capex includes INR 5-7 crores towards operationalizing one SOCE unit under the FOSO model. - Capex planned for operationalizing new hospitals, specifically Nashik hospital expected in late FY23 or early FY24. - Mumbai hospital project is planned for the next 3-4 years but still awaiting site visit approvals from the Joint Commission and BMC. - Investment in building capabilities in other specialties alongside marketing spend increased by 100 bps compared to last year. - Strategic investments include expanding SOCE franchise hospitals with plans to reach over 50 units in 3-4 years. - Continuous investment in sales, engineering, and supply chain to drive growth and improve efficiencies, especially for the implant business.

- Hospital business EBITDA margin is expected to expand in coming quarters due to anticipated revenue growth. - SOCE franchisee vertical aims to establish over 50 franchise hospitals across India within 3-4 years, with surgery count and revenue growing ~40% YoY this quarter. - Implant business targets 50%+ revenue growth in FY24, backed by new product launches and market expansions in U.S., India, Southeast Asia, Latin America, and Indonesia. - Shalby Advanced Technologies (SAT) aims for mid-single-digit EBITDA margin profitability in FY24 and $100 million revenue in 5 years. - Home Care segment expects to grow from current 1.5-2% to 5% of hospital top line over 2-3 years. - Hospital occupancy and surgery counts are rising, with hospital occupancy at 50% and surgery growth at 14% YoY. - ARPOB levels sustained due to favorable specialty mix and insurance renegotiations, supporting revenue growth.

- Hospital business expected to sustain double-digit growth in inpatient and surgery counts, with occupancy rates improving to 50% in Q1 FY '24 and likely to ramp up further. - EBITDA margin of 23% in hospital operations expected to expand in coming quarters due to higher revenue and investments in new specialties. - Implant business aims for 50%+ revenue growth in FY '24, targeting $18 million full-year revenue with new product launches and market expansion, including $0.35-$0.5 million expected sales from Indonesia. - SOCE franchisee units to grow from 4 to 8-9 operational units by end of FY '24, with surgeries and revenue growing 40%+ YoY. - Home Care segment is growing rapidly (71% revenue growth Q1 YoY) and expected to contribute up to 5% of hospital topline in 2-3 years. - Overall, positive outlook with EBITDA and profits expected to improve driven by operational efficiencies, new capex, and expanded geographic presence.

- The order from Indonesia is around $350,000 to $0.5 million expected to be completed this year, with the first order at about $100,000+. - Some orders from Argentina and Paraguay have been delayed due to regulatory approval delays. - There is no explicit detailed mention of a total current or expected order book value in the transcript. - The implant business plans to grow 50%+ over last year with a full-year target of $18 million revenue. - The Ambition Knee, a major product launch expected to be a game changer in India and Southeast Asia, was delayed due to instrument manufacturing issues but is expected to launch in the coming months, which will likely boost future orders. - Overall, the company is confident about growth and new markets for its implant business and expects stronger sales in the second half of the year.